Contact: Kimberly Hardwrick
3625 Cumberland Blvd SE
12 articles with UCB
UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy
UCB invested €25 million ($29.3 million) and as majority shareholder, will sit on the Board of Directors of Nile with future opportunities to acquire insights and data from Nile's platform
UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020
UCB's VIMPAT, recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS), will be highlighted during virtual symposium featuring expert neurology panel
Branded digital companions are available through Medisafe's advanced platform to UCB members currently enrolled in its antiepileptic drug therapy
doc.ai and UCB Biopharma Team Up to Develop Breakthrough Artificial Intelligence Models to Advance Care
New digital health trial will leverage state-of-the-art tech to detect and predict myasthenia gravis symptom patterns and flares
UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy
These approvals further help patients with epilepsy who may have had limited treatment options in the past, while reinforcing UCB's leadership in transforming epilepsy care
UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms
Acquisition of Handl Therapeutics BV augments UCB's existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid technology platform and capabilities
This morning, the company announced it bolstered its own gene therapy activities with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company.
- First results from the Phase 3 BE SURE study will be presented showing superior skin clearance with bimekizumab compared to Humira® (adalimumab) in patients with moderate-to-severe plaque psoriasis - Two oral presentations from the Phase 3 BE VIVID study show consistent levels of skin clearance with bimekizumab irrespective of patient demographics, disease characteristics and prior treatment experience, and an acceptable safety profile based on an integrated analysis across Phase 2 a
10/16/2020UCB is investing more than £1 billion over five years to expand its research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis
Tennis Champion Caroline Wozniacki and UCB Launch Advantage Hers Campaign for Women with Chronic Inflammatory Diseases
Grand Slam winner Caroline Wozniacki is the highest-ranking female athlete known to have been diagnosed with rheumatoid arthritis whilst still playing professional tennis
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.